FDA Approves Genentech ’s Tecentriq as First-Ever Therapy for a Certain Advanced Rare Sarcoma Called Alveolar Soft Part Sarcoma (ASPS)

South San Francisco, CA -- December 9th, 2022 -- Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) for the treatment of adult and pediatric patients...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news